Verbesserung der Lebensqualität im Alter: Ergebnisse einer plazebokontrollierten Studie zur Wirksamkeit und Verträglichkeit von Lecithin in flüssiger Darreichungsform bei Patienten mit Beeinträchtigung der kognitivenFunktionen

Lecithin, a precursor of the neurotransmitter acetylcholine, has a positive effect on brain and memory functions. In a prospective, randomized, double-blind study, the effect of buerlecithin® fluid (BLF) was investigatedin comparison with placebo in patients with mild cognitive disorders. A total of 96 ambulatory patients (> 55 years) were admitted to the study. Treatment duration was 84 days. In both treatment groups, a clear improvement in all the cognitive parameters tested was seen. The main target measure, the overall Sandoz Clinical Assessment Geriatric (SCAG) score improved by 18.7 (test substance) and 16.4 (placebo) points (p = 0.1620). A statistically relevant improvement of the secondary target parameter, response in the SCAG score, was achieved with BLF (85.4%) in comparison with placebo (62.5%) (p=0.018). Furthermore, BLF demonstrated significant superiority in a number of the other target measures. The study also confirmed the very good tolerability of BLF.